The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 97.00
Bid: 96.00
Ask: 98.00
Change: 1.50 (1.55%)
Spread: 2.00 (2.083%)
Open: 96.50
High: 98.00
Low: 98.00
Prev. Close: 96.50
DXRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

10 Nov 2020 16:32

RNS Number : 8887E
Diaceutics PLC
10 November 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Diaceutics Plc

 

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Danske Bank A/S

City and country of registered office (if applicable)

DK - 1092 Copenhagen

4. Full name of shareholder(s) (if different from 3.)v

Name

 

DANSKE INVEST MANAGEMENT COMPANY (SOCIÉTE ANONYME)/DANSKE INVEST FCP LUXEMBOURG

 

DANSKE INVEST FUND MANAGEMENT LTD./DANSKE INVEST FINLAND

 

PROXY VOTES SUPPLIED BY INVESTERINGSFORENINGEN DANSKE INVEST

 

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

09-11-2020

6. Date on which issuer notified (DD/MM/YYYY):

10-11-2020

7. Total positions of person(s) subject to the notification obligation4.77109

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

3.10

 

3.10

 

84,068,923.00

 

Position of previous notification (if

applicable)

 

N/A

 

N/A

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BJQTGV64

 

2,605,164.00

 

 

3.10

SUBTOTAL 8. A

2,605,164.00

 

3.10

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Danske Invest FCP Luxembourg

13, rue Edward Steichen

L-2540 Luxembourg

- A mutual fund under management of

Danske Invest Management Company (Société Anonyme)

13, rue Edward Steichen

L-2540 Luxembourg

- a subsidiary 100% owned by

Danske Bank International S.A,

13, rue Edward Steichen

L-2540 Luxembourg

- a subsidiary 100% owned by Danske Bank A/S

 

Danske Invest Finland

Hiililaiturinkuja 2, P.O. Box 1553,

FIN-00180 Helsinki

Finland

- a mutual fund under management of

Danske Invest Fund Management Ltd.

Hiililaiturinkuja 2, P.O. Box 1553,

FIN-00180 Helsinki

Finland

- a subsidiary 100% owned by

Danske Bank plc

Hiililaiturinkuja 2, P.O. Box 1568

00075 Danske Bank, Finland

- a subsidiary 100% owned by Danske Bank A/S

Proxy shares given to Danske Capital, a division of Danske Bank A/S (so no separate legal identity) by:

 

lnvesteringsforeningen Danske Invest

Parallelvej 17

DK-2800 Kgs. Lyngby

Denmark

10. In case of proxy voting, please identify:

Name of the proxy holder

DANSKE Capital, a division of Danske Bank A/S

The number and % of voting rights held

Danske Invest Europa Small cap

(1,076,798.00 shs/votings rights = 1.28%)

 

Danske Invest Europa Small cap AKK

(94,988.00 shs/votings rights = 0.11%)

The date until which the voting rights will be held

No set expiry date

11. Additional informationxvi

 

Place of completion

DK - 1092 Copenhagen K

Date of completion

10-11-2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLQBLFFBFLXFBB
Date   Source Headline
1st May 20247:00 amRNSNotice of Results & Presentations
30th Apr 20247:00 amRNSPDMR Shareholding/SIP and TVR
9th Apr 20247:00 amRNSAppointment of Amie Mc Neice as VP of Marketing
5th Apr 20241:40 pmRNSBlock Listing Return
3rd Apr 20247:00 amRNSPDMR Shareholding/Share Incentive Plan
2nd Apr 20247:00 amRNSDirector/PDMR/PCA Shareholding & TR1
21st Mar 20247:00 amRNSSignificant upgrade to Diaceutics' DXRX platform
19th Mar 20247:00 amRNSDiaceutics forms landmark industry Forum
7th Mar 20247:00 amRNSDirector/PDMR Shareholding
1st Mar 20249:00 amRNSPDMR Shareholding / SIP and TVR
27th Feb 20247:00 amRNSExpanded lab network and data capabilities
14th Feb 20241:00 pmRNSDiaceutics PLC - Strategic alliance with KPMG
5th Feb 20247:00 amRNSAppointment of VP, Scientific & Medical Services
1st Feb 202412:31 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
30th Jan 20247:00 amRNSDiaceutics PLC – Trading Update
25th Jan 20241:16 pmRNSExercise of Warrant & Total Voting Rights
19th Jan 20247:00 amRNSDiaceutics PLC – Financial Calendar Update
29th Dec 20231:18 pmRNSPDMR Shareholding/Share Incentive Plan
30th Nov 202312:59 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
30th Nov 20237:00 amRNSDiaceutics to attend Stifel Conference in NYC
21st Nov 202311:13 amRNSNotification of Major Holdings
31st Oct 202312:38 pmRNSPDMR Shareholding/SIP & Total Voting Rights
11th Oct 20231:47 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
2nd Oct 20233:59 pmRNSBlock Listing Application to AIM
29th Sep 202311:19 amRNSHolding(s) in Company
26th Sep 20237:00 amRNSDiaceutics PLC – Half Year Results
26th Sep 20237:00 amRNSDiaceutics PLC - Planned CEO Transition
21st Sep 20232:37 pmRNSDiaceutics PLC – Directorate Changes
7th Sep 20237:00 amRNSAttending 10th Annual HealthTech Investment Forum
5th Sep 20237:00 amRNSNotice of Interim Results and Presentations
30th Aug 20232:56 pmRNSPDMR Shareholding/Share Incentive Plan
29th Aug 20237:00 amRNSDiaceutics launches daily alerts for DXRX platform
4th Aug 20237:00 amRNSCanaccord Genuity 43rd Annual Growth Conference
31st Jul 20233:19 pmRNSPDMR Shareholding/Share Incentive Plan
25th Jul 20237:00 amRNSTrading Update and Notice of Results
29th Jun 202312:07 pmRNSPDMR Shareholding/Share Incentive Plan
6th Jun 20237:00 amRNSPurchase and Sale of Shares and PDMR Shareholdings
5th Jun 20237:00 amRNSUSD 10.1 million multi-year enterprise engagement
31st May 20235:13 pmRNSPDMR Shareholding/Share Incentive Plan
19th May 202310:16 amRNSIssue of Share Options/PDMR Shareholdings
18th May 202311:46 amRNSResults of Annual General Meeting
11th May 20236:22 pmRNSPDMR Shareholdings
4th May 202310:34 amRNSPDMR shareholdings
28th Apr 20236:03 pmRNSPDMR Shareholding/Share Incentive Plan
26th Apr 20235:03 pmRNSPDMR Shareholding
25th Apr 20235:45 pmRNSNotice of AGM and Posting of Annual Report
17th Apr 20237:00 amRNSFinal Results
3rd Apr 20232:43 pmRNSPDMR Shareholding / Share Incentive Plan
20th Mar 20237:00 amRNSNotice of Results and Presentations
13th Mar 202310:15 amRNSRestoration - Diaceutics PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.